tetano
Editor, Senior Moderator
Neurol Sci
. 2021 Jul 28.
doi: 10.1007/s10072-021-05461-2. Online ahead of print.
Delirium in COVID-19 patients: a multicentric observational study in Italy
Giovanni Martinotti[SUP] 1 2 [/SUP], Laura Bonanni[SUP] 1 [/SUP], Stefano Barlati[SUP] 3 [/SUP], Andrea Miuli[SUP] 4 [/SUP], Gianna Sepede[SUP] 1 [/SUP], Davide Prestia[SUP] 5 [/SUP], Alice Trabucco[SUP] 5 [/SUP], Claudia Palumbo[SUP] 6 [/SUP], Alessandra Massaro[SUP] 6 [/SUP], Martina Olcese[SUP] 7 [/SUP], Damiano D'Ardes[SUP] 8 [/SUP], Francesco Cipollone[SUP] 8 [/SUP], Mario Amore[SUP] 5 [/SUP], Emi Bondi[SUP] 6 [/SUP], Mirella Russo[SUP] 1 [/SUP], Claudia Carrarini[SUP] 1 [/SUP], Marco Onofrj[SUP] 1 [/SUP], Stefano Luca Sensi[SUP] 1 [/SUP], Antonio Vita[SUP] 3 [/SUP], Massimo di Giannantonio[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Although recent data show that SARS-CoV-2 infection seems to affect the central nervous system (CNS), little is known about the neuropsychiatric effects resulting from this condition. In addition to the well-known neurotrophism of coronaviruses, recent evidence shows also that the "cytokine storm" induced by the infection is at the basis of the neuroinflammation of the CNS. Furthermore, prolonged hospitalization, polypharmacotherapy, and isolation could be at the basis of the onset of delirium in hospitalized COVID patients. This multicentric observational study explores the incidence of the onset of delirium in an Italian cohort of SARS-CoV-2 positive inpatients.
Methods: Data were collected in the COVIDhospitals of Brescia, Bergamo, Chieti, and Genova. Different socio-demographic, medical, neurological, and pharmacological parameters were collected. As a rapid screening for delirium, the 4AT scale was used. Eighty COVID-19 inpatients (mean age 74.7 ± 14.5 years) met the inclusion criteria (confirmed positivity to the SARS-CoV-2 virus; the presence of delirium and/or psychomotor agitation and/or new onset of other neuropsychiatric symptoms during hospitalization).
Results: The majority of these patients (68.8%) had "hyperactive delirium" subtype. Polypharmacotherapy, current treatment with corticosteroids, and higher age were associated with delirium severity.
Conclusion: These data provide an insight into the onset of delirium among COVID-19 patients underlining the need for monitoring, especially in elderly patients, the neuropsychiatric symptoms, and the therapy in order to have shorter hospitalization times and better outcomes.
Keywords: COVID-19; Delirium; Neuroinflammation; SARS-CoV-2 infection.
. 2021 Jul 28.
doi: 10.1007/s10072-021-05461-2. Online ahead of print.
Delirium in COVID-19 patients: a multicentric observational study in Italy
Giovanni Martinotti[SUP] 1 2 [/SUP], Laura Bonanni[SUP] 1 [/SUP], Stefano Barlati[SUP] 3 [/SUP], Andrea Miuli[SUP] 4 [/SUP], Gianna Sepede[SUP] 1 [/SUP], Davide Prestia[SUP] 5 [/SUP], Alice Trabucco[SUP] 5 [/SUP], Claudia Palumbo[SUP] 6 [/SUP], Alessandra Massaro[SUP] 6 [/SUP], Martina Olcese[SUP] 7 [/SUP], Damiano D'Ardes[SUP] 8 [/SUP], Francesco Cipollone[SUP] 8 [/SUP], Mario Amore[SUP] 5 [/SUP], Emi Bondi[SUP] 6 [/SUP], Mirella Russo[SUP] 1 [/SUP], Claudia Carrarini[SUP] 1 [/SUP], Marco Onofrj[SUP] 1 [/SUP], Stefano Luca Sensi[SUP] 1 [/SUP], Antonio Vita[SUP] 3 [/SUP], Massimo di Giannantonio[SUP] 1 [/SUP]
Affiliations
- PMID: 34318364
- DOI: 10.1007/s10072-021-05461-2
Abstract
Introduction: Although recent data show that SARS-CoV-2 infection seems to affect the central nervous system (CNS), little is known about the neuropsychiatric effects resulting from this condition. In addition to the well-known neurotrophism of coronaviruses, recent evidence shows also that the "cytokine storm" induced by the infection is at the basis of the neuroinflammation of the CNS. Furthermore, prolonged hospitalization, polypharmacotherapy, and isolation could be at the basis of the onset of delirium in hospitalized COVID patients. This multicentric observational study explores the incidence of the onset of delirium in an Italian cohort of SARS-CoV-2 positive inpatients.
Methods: Data were collected in the COVIDhospitals of Brescia, Bergamo, Chieti, and Genova. Different socio-demographic, medical, neurological, and pharmacological parameters were collected. As a rapid screening for delirium, the 4AT scale was used. Eighty COVID-19 inpatients (mean age 74.7 ± 14.5 years) met the inclusion criteria (confirmed positivity to the SARS-CoV-2 virus; the presence of delirium and/or psychomotor agitation and/or new onset of other neuropsychiatric symptoms during hospitalization).
Results: The majority of these patients (68.8%) had "hyperactive delirium" subtype. Polypharmacotherapy, current treatment with corticosteroids, and higher age were associated with delirium severity.
Conclusion: These data provide an insight into the onset of delirium among COVID-19 patients underlining the need for monitoring, especially in elderly patients, the neuropsychiatric symptoms, and the therapy in order to have shorter hospitalization times and better outcomes.
Keywords: COVID-19; Delirium; Neuroinflammation; SARS-CoV-2 infection.